Articles tagged with Drug Discovery
Researchers found a new approach to treating chronic and debilitating neuropathic pain by blocking the alpha9alpha10 nicotinic acetylcholine receptor. The study suggests a previously unrecognized molecular mechanism for treating this condition, which affects hundreds of millions of people worldwide.
Diarrheal diseases kill over 2 million children annually, and the Institute for OneWorld Health aims to combat this with novel anti-secretory drugs. The $46 million grant will support the development of new treatments to complement traditional approaches.
A British drug discovery company is teaming up with a Brazilian firm to search for new medicines in the Amazonian and Atlantic rain forests. The partnership aims to combat diseases such as tuberculosis, avian flu, and tropical illnesses like hepatitis C and Chagas disease.
Researchers at Thomas Jefferson University have discovered a new way to sidestep gleevec resistance in leukemia cells. By reactivating the protein C/EBP-alpha, they found that leukemia development is halted. This discovery could lead to new treatment strategies for leukemias resistant to gleevec and other cancers.
J-P Garnier, GSK CEO, emphasizes the company's commitment to providing affordable HIV drugs and vaccines for diseases affecting the developing world. He highlights GSK's efforts to introduce modern HIV drugs at lower prices and protect innovation through patents.
Researchers have discovered that C. albicans can neutralize antifungal drugs by duplicating one arm of chromosome 5 and deleting the other, creating an 'isochromosome'. This finding could lead to strategies for making currently available antifungal drugs more effective.
Researchers at UCLA have discovered how the drug Ro15-4513 binds to specific receptors in the brain to block alcohol's effects on motor coordination. This breakthrough may lead to the development of sober-up pills, alcohol addiction medications, and treatments that harness the beneficial effects of moderate alcohol consumption.
Researchers at Michigan State University have developed a new, eco-friendly method for producing Taxol, a top-selling cancer-fighting drug. By harnessing enzymes from the Pacific yew tree and using water-based chemicals, they aim to reduce waste and minimize environmental impact.
William Fenical, a Scripps Institution of Oceanography professor, has been awarded the Ernest Guenther Award for his pioneering work on marine natural products chemistry. His research has led to the discovery of potent anticancer agents and anti-inflammatory drugs from ocean sea floor bacteria.
Researchers at UCSB have discovered that rapamycin, a widely available immunosuppressant, can strongly reduce cyst growth in kidneys affected by polycystic kidney disease (PKD). The treatment was found to shrink cysts and retain kidney function in mice with PKD.
The American Chemical Society has awarded a national recognition to a prominent chemist for their groundbreaking work in medicinal chemistry. Anderson has made significant contributions to the development of statins and HIV treatments, including Zocor and Crixivan.
Researchers at Georgia Institute of Technology have developed an algorithm that creates accurate three-dimensional models of over 900 GPCRs, a class of proteins targeted by many drugs. These models could help scientists discover new drug compounds more efficiently, and are now freely available to noncommercial users.
Researchers have created temperature-sensitive capsules that can release drugs at different rates, with the release rate controlled by the amount of wrinkling. The solution to cool the capsules without harming surrounding tissue lies in newly discovered nanoparticles chilled through magnetic cooling.
Researchers at Rensselaer Polytechnic Institute have successfully synthesized hundreds of milligrams of heparin using engineered enzymes and co-factor recycling. This breakthrough could enable the widespread use of synthetic heparin in human medical treatments, reducing reliance on animal-derived products.
Researchers at Northwestern University have developed a new compound that selectively inhibits pro-inflammatory proteins called cytokines by glia, slowing or reversing neuroinflammatory cascade progression. The compound also restored normal synaptic function and attenuated Alzheimer's-like behavioral deficits in mice.
Researchers believe that analyzing Medicare data will help assess medication use in real-life conditions, improving the nation's ability to understand risks and benefits of drug treatment. This can lead to increased data on whether drugs are used as intended and their potential risks.
A new biochip tool called MetaChip can analyze drug candidates for toxicity and eliminate harmful ones before they advance to pre-clinical stages. The technology mimics the effects of metabolism in the human liver, enabling early detection of toxic compounds that could be difficult to predict or find with current testing methods.
The collaboration aims to uncover the genetic basis underlying important agricultural traits in rice. By identifying sequence variation between major rice varieties, researchers can associate DNA variations with traits like drought resistance or vitamin content, ultimately helping to breed more resilient and nutritious rice strains.
Tomio Joins Blackwell Publishing to Advance Chemical Biology & Drug Design, Focusing on Smart Chemistry and Innovative Drug Development. Tomio brings extensive experience in small-molecule drug discovery and multidisciplinary research at ARIAD Pharmaceuticals.
GSK has successfully implemented a new automated process for the early phase of drug discovery, using InforSense KDE to retrieve and analyse data rapidly. This technology allows chemists to modify complex analytic workflows and access data from distributed databases, significantly improving their ability to respond to scientific needs.
Lipman Hearne biochemist will receive a $500,000 MacArthur grant for outstanding contributions to drug research. The award recognizes their exceptional originality and dedication to their creative pursuits.
Researchers employed a bacteriophage to learn how an HIV protein responds to new anti-viral molecules, identifying compounds with potential to overcome drug resistance. This approach enables faster and more effective drug discovery for other anti-viral therapies.
Rensselaer researchers have developed a predictive modeling approach that can determine protein behavior for use in bioseparation applications. The model uses molecular information obtained from the protein structure to predict adsorption isotherm parameters and chromatographic behavior, replicating experimental results.
Researchers have discovered a potential new target for cannabis-derived drugs to treat inflammatory bowel disease (IBD), which causes inflammation in the gastrointestinal tract. Cannabis-based medicines could help heal the gut lining, alleviating symptoms such as pain and weight loss.
In a unique project, scientists collaborated with Fijian villagers to explore, protect, and generate income from their coral reef. The project involves planting synthetic rock that becomes naturally covered by desirable species, providing villagers with financial benefits.
Mayo Clinic researchers report a new mechanism behind thiopurine metabolism, a protein deficit caused by misfolded proteins that disrupts enzyme function. The discovery offers promising new directions for predicting genetic changes and altering drug effects.
The study reveals key connections between metabolic disease pathways and aging, identifying genes and mechanisms that can be targeted for drug discovery. Targeting these pathways may uncover novel therapeutic targets and drugs to treat metabolic diseases and potentially impact the progression of aging.
Researchers believe gut microbes influence how medicines affect the body, leading to individualized treatments and drug discovery. Changes in gut microbiome composition may impact medication effectiveness between individuals.
The Harbor Branch expedition aims to explore the Straits of Florida in search of organisms that produce chemicals with potential to cure diseases like cancer and Alzheimer's. The team will conduct submersible dives on the Cay Sal Bank and Miami Terrace to gather samples and discover new species.
Virginia Tech researchers have made a breakthrough in using supercritical fluid chromatography to separate polar and ionic compounds, paving the way for green-chemistry techniques in drug development. The discovery uses carbon dioxide-based fluids with added polar solvents containing ionic components.
A new discovery may lead to more precise cancer treatment by creating damaged DNA that is deadly to cancer cells. Researchers created synthetic double-stranded DNA with specific chemical characteristics and exposed it to long wavelength light, selectively triggering the damage process.
The production of sub-standard and fake drugs is a vast and under-reported problem that causes unnecessary deaths and illnesses. The authors argue that a multifaceted approach is needed to control the global epidemic of counterfeit and substandard drugs, including mandatory reporting by drug companies and governments.
Researchers found that a genetic component of the body's internal clock affects immune cells' sensitivity to cyclophosphamide, an anti-cancer drug. The study's findings may lead to more effective and less toxic cancer treatments.
A study led by Elena Bagley and Macdonald Christie found that a transporter molecule for the neurotransmitter GABA is responsible for opioid withdrawal symptoms. Inhibiting this molecule or protein kinase A eliminates hyperexcitability in PAG neurons.
Scientists have discovered that gamma-secretase, a key enzyme involved in Alzheimer's disease, has diverse tissue-specific activity. This finding opens up new possibilities for developing targeted treatments by focusing on the inactivation of specific sub-units, which may reduce side effects.
A decentralized, Web-based, community-wide effort called the Tropical Diseases Initiative (TDI) proposes an open-source approach to discovering new drugs for neglected diseases. By adopting this model, scientists from laboratories, universities, and corporations can work together to develop affordable treatments for tropical diseases s...
Yale researcher Nita Maihle has been awarded a visiting professorship at Pfizer, where she will collaborate on cancer research for 12 weeks. The program aims to improve the drug discovery process and facilitate associations among Yale investigators and Pfizer staff.
Researchers at Harvard University have developed a new method called cytological profiling that uses automated microscopic imaging to track the broad effects of drugs on cells. This technique allows for high-throughput analysis, enabling scientists to quickly identify promising drugs and streamline early phases of drug discovery.
Researchers discovered a new class of compounds, aminopyridazines, that target neuroinflammation and neuronal loss in Alzheimer's disease. The compounds inhibit glial activation and reduce oxidative stress, leading to decreased neuron loss and improved cognitive function.
Researchers at Duke University Medical Center have created a novel drug-antidote strategy that provides greater control of drug action. The breakthrough enables the development of matched drug-antidote pairs at the beginning of the drug development process, allowing for more precise treatment.
The Oregon Health & Science University has launched a new Bioanalytical Shared Resource (BSR) lab, supported by the $500 million Oregon Opportunity initiative. The BSR provides advanced analytical services for drugs and molecules, enabling researchers to quickly move from laboratory to patient testing.
Brown University scientists discover a malaria drug that precisely blocks specific connexins in the brain and eye, which may help shed light on the cause of epilepsy and seizures. The breakthrough could also lead to new treatments for other neurological conditions.
Studies suggest that over-the-counter 'Plan B' emergency contraception may lead to increased risk-taking behaviors and reduced comprehensive healthcare access for US women. The drug has an 11-25% failure rate, resulting in additional pregnancies and abortions.
Researchers have developed a genetic code that enables the evolution of synthetic molecules, revolutionizing drug discovery. By creating a library of nonbiological origin compounds, scientists can identify novel drugs and disrupt cellular processes.
Researchers at Rensselaer Polytechnic Institute developed a software program that quickly identifies molecules with sound medicinal properties. The software uses shortcuts in chemistry and math to rapidly analyze vast molecular databases, predicting which compounds have the right chemical features for specific therapies.
Researchers use computer methods and electron microscopy to understand how molecular machines interact and work together in cells. By building assembly plans for individual machines, they can connect them to form a network, providing insights into cellular structures and functions.
Researchers have identified orlistat as an inhibitor of fatty acid synthase, a key enzyme in cancer cell metabolism. This discovery holds promise for developing new treatments for prostate, breast, and colon cancers by inhibiting the enzyme's activity with orlistat.
Researchers at Thomas Jefferson University have discovered a complex of two proteins in the intestine that plays a crucial role in cholesterol transport. Treating mice with ezetimibe disrupts this complex, leading to impaired cholesterol absorption, suggesting new therapeutic possibilities.
The new assay uses fluorochrome binding to detect malaria parasites in cell culture, providing a safer and more cost-effective alternative to current methods. This breakthrough has the potential to drastically reduce the price tag for drug discovery and promote research into tropical parasitic diseases.
The Emory-GSK-NIMH Collaborative Mood Disorders Initiative will develop innovative models for basic and clinical research in mood disorders. Scientists at NIMH will create clinical models to assess novel antidepressants, while Emory faculty will develop preclinical models of fear, anxiety, and depression.
Researchers at UCL's Wolfson Institute for Biomedical Research have developed a new drug to treat enlarged prostate with virtually no hormonal side effects. The treatment can both relax the prostate and prevent its growth, offering a major advance in treating a condition affecting millions of men worldwide.
A new anti-rejection drug, CP-690,550, has shown promise in controlling the immune system without severe side effects. The Stanford team discovered the drug by targeting a specific pathway in immune cells, which may lead to its use in treating autoimmune diseases.
NIAMS researchers collaborated with Pfizer to develop and test a new immunosuppressant drug, CP-690,550, which targets the immune system without causing toxic side effects. The study showed promising results in mice and monkeys, suggesting potential for treating autoimmune diseases such as lupus and rheumatoid arthritis.
Conotoxins have extraordinary promise for developing powerful new drugs, including treatments for pain, cancer, epilepsy, and depression. However, habitat loss and uncontrolled exploitation threaten the extinction of cone snail species, which are a valuable source of these medicines.
Researchers at OHSU discovered that HIV-encoded protein Vif neutralizes human protein APOBEC3G, which would inactivate HIV if present. This finding could lead to the development of targeted anti-HIV drugs and provide insights into the body's innate protection system.
Eight IU Chemistry faculty members, including Andrew Leavitt and Lisa Lewis, have been recognized for their outstanding contributions to undergraduate research. They will deliver 25-minute talks at the symposium, which also features a keynote address by Pfizer GRD Vice President Bruce Roth.
A renowned chemist has synthesized epothilone, a compound derived from bacteria, promising to replace taxol in treating cancer. His successful 25-step synthesis has garnered interest from pharmaceutical companies, paving the way for potential clinical trials and widespread use.
A new theory suggests that human metabolism operates like a pinball machine, influencing drug toxicity and disease development. The researchers used metabonomics to study global human metabolism and its interactions with drugs, environment, and gut microflora.
Scientists identify several novel pairings with significant therapeutic promise, including a combination that kills drug-resistant yeast while harming human cells. The approach uses high-throughput screens to rapidly identify synergistic combinations that produce desired therapeutic effects.
A study by Purdue University researchers found that patients experience more improvement in quality of life when taking more expensive pharmaceuticals, regardless of the ailment. The study suggests that government interference with market prices may reduce long-term drug development and potentially lead to fewer quality drugs.